SCHEMBL6804100

SCHEMBL6804100

CCOc1cc(-c2ccc(C(=O)OC)cc2)nn1CCOc1ccc(-c2ccc(F)cc2F)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.39
GCGR P47871 1/20 0.38
GIPR P48546 1/20 0.38
SCN9A Q15858 3/20 0.37
CTSA P10619 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
TP53 P04637 1/20 0.37
MDM2 Q00987 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805484 0.92 TP53 (0.45) GCGRGIPRCTSATP53MDM2
SCHEMBL6809221 0.91 MEN1 (0.41) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6600937 0.91 TP53 (0.41) NLRP3GCGRGIPRCTSAALDH1A1
SCHEMBL6607403 0.89 NLRP3 (0.43) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6602643 0.85 KMT2A (0.44) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6600968 0.85 MEN1 (0.43) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6800862 0.84 NLRP3 (0.43) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6601799 0.84 MAPT (0.42) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6601520 0.84 NLRP3 (0.42) NLRP3GCGRGIPRALDH1A1MAPT
SCHEMBL6602104 0.84 NLRP3 (0.44) NLRP3GCGRGIPRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 NLRP3 1134/4885GCGR 2460/4885GIPR 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.